MedWatch

Boehringer Ingelheim and partner launches stage II trials for NASH and obesity

In collaboration with Zealand Pharma, Boehringer Ingelheim is advancing to stage II trials with the drug candidate BI 456906 which is currently being tested as a treatment for type II diabetes. Now, the drug will prove its worth as a treatment for the fatty liver disease NASH and obesity.

Photo: Zealand Pharma / PR

Danish biotech company Zealand Pharma and its collaborative partner, German pharmaceutical company Boehringer Ingelheim, are initiating stage II trials with the drug candidate BI 456906.

They will take the shape of a once-weekly treatment for obesity on the one hand, and of a treatment for the fatty liver disease NASH on the other, according to a press statement from Zealand Pharma on Tuesday afternoon.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs